Renal Anemia | Treatment Algorithms: Claims Data Analysis | US | 2024

Renal anemia is a common complication of chronic kidney disease (CKD). The primary goal of treatment of renal anemia is to increase and maintain Hb levels and reduce the risk of complications of chronic hypoxia, high mortality rates, and cardiovascular disease. Renal anemia nondialysis patients are initially treated with oral iron, followed by IV iron; ESAs are prescribed as third-line therapy. Dialysis patients usually receive IV iron therapy followed by ESAs, and HIF-PH inhibitors are prescribed in the third line when CKD worsens and patients are no longer responding to ESAs. In the United States, GSK’s Jesduvroq (daprodustat) was the first HIF-PH inhibitor approved for renal anemia patients who have been on dialysis for at least four months, although it was not approved for use in the nondialysis population. Several ESAs and iron supplements are available, with varying degrees of commercial success. This report provides important insights into how these agents are used in the management of renal anemia and how practices are evolving.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed renal anemia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed renal anemia patients?
• How have ESAs been integrated into the treatment algorithm, and what is their source of business?
• What percentage of renal anemia patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of renal anemia patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key drugs: Epogen / Procrit, Retacrit, Aranesp, Mircera, Auryxia, iron supplements

KEY FEATURE

Dashboard featuring interactive visuals, easy navigation, and expanded analyses